Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Lineage Cell Therapeutics, Inc., a pioneering biotechnology company based in the United States, focuses on developing innovative cell therapies for the treatment of degenerative diseases. Founded in 2015, Lineage has made significant strides in the regenerative medicine sector, particularly in the fields of ophthalmology and neurology.
The company’s core offerings include advanced cell-based therapies, notably its proprietary retinal pigment epithelium (RPE) cells aimed at treating conditions like age-related macular degeneration. Lineage's unique approach leverages its expertise in pluripotent stem cell technology, positioning it as a leader in the regenerative medicine landscape. With a commitment to transforming patient care, Lineage Cell Therapeutics continues to achieve notable milestones, solidifying its reputation in the competitive biopharmaceutical industry.
-24 vs industry average
Lineage Cell Therapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Lineage Cell Therapeutics, Inc. yet.
Lineage Cell Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards.
As there are no emissions data or reduction initiatives available, it is unclear how Lineage Cell Therapeutics is addressing its carbon footprint or contributing to climate action within the biotechnology sector. The lack of reported emissions and commitments may reflect a broader trend in the industry, where companies are increasingly being urged to disclose their environmental impact and set measurable targets for reduction.
No climate goals have been disclosed for Lineage Cell Therapeutics, Inc. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more